BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

CPHI India 2026 opens in Delhi, showcasing innovations across pharmaceutical ingredients and formulations

24 November 2026 | News

Nine free trade agreements covering 38 nations could unlock $100 billion in pharmaceutical trade opportunities



CPHI India 2026, one of the country's premier pharmaceutical industry exhibitions, commenced on 23 November, 2026 at IICC, Yashobhoomi, Dwarka, Delhi. This year's edition introduces an expanded two-venue format, with CPHI India taking place from 23–25th November at IICC, Yashobhoomi, and PMEC India scheduled from 24–26th November at India Expo Mart (IEML), Greater Noida.

Together, the co-located exhibitions bring the pharmaceutical ecosystem onto a common platform, connecting stakeholders across ingredients, formulations, processing machinery, packaging and manufacturing technologies.

The combined platform features over 2,000 exhibitors and is expected to attract 50,000 visitors from more than 120 countries, with strong international participation from markets including Belgium, China, Germany, Italy, Japan, South Korea, Switzerland, the United Kingdom and the United States, among others. This reflects the global reach of the platform and its role in connecting India's pharmaceutical industry with international markets.

The grand inauguration was graced by an esteemed lineup of industry leaders, policymakers, and global representatives. The distinguished guests included Dr Chandrashekar Ranga, Joint Drug Controller India, CDSCO; K. Raja Bhanu, Director General Pharmexcil; Harish K Jain, President – FOPE; Anil Matai, Director General OPPI; alongside Orhan Caglayan - Executive Vice President - Pharma, Informa Markets B.V.; Yogesh Mudras, Managing Director, Informa Markets in India and Rahul Deshpande, Sr. Group Director, Informa Markets in India.

Dr Chandrashekar Ranga, Joint Drugs Controller (India), Central Drugs Standard Control Organization (CDSCO) said
"The proposed addition of 1,500 scientific personnel at CDSCO and a unified digital regulatory platform are aimed at accelerating approvals while maintaining stringent quality safeguards. The 10th edition of the Indian Pharmacopoeia, incorporating 121 new monographs and taking the total to 3,340, further reinforces the country's regulatory capabilities. Alongside greater API self-reliance, indigenous CAR-T cell therapies and WHO Maturity Level 3 recognition for vaccine regulation, these reforms position India to advance pharmaceutical innovation, patient safety and international regulatory cooperation."

Key exhibitors participating at CPHI India include **Pharmexcil – India pavilion, Morepen Laboratories Limited, Hetero Drugs, Aurobindo Pharma, Titan Biotech Ltd, Dr. Reddys Laboratories Ltd and more.**

Looking ahead, India's pharmaceutical sector is poised for a decisive shift from volume-driven generics to high-value, innovation-led manufacturing. Valued at **$60 billion in FY2025–26**, the domestic pharmaceutical market is projected to more than double to **$130 billion by 2030**, underpinned by strong domestic demand, rising healthcare penetration, and sustained foreign direct investment.